Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) EBT Margin (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed EBT Margin for 16 consecutive years, with 266.88% as the latest value for Q4 2025.

  • For Q4 2025, EBT Margin rose 9963.0% year-over-year to 266.88%; the TTM value through Dec 2025 reached 312.25%, down 13937.0%, while the annual FY2025 figure was 312.25%, 14251.0% down from the prior year.
  • EBT Margin hit 266.88% in Q4 2025 for Sangamo Therapeutics, up from 6039.76% in the prior quarter.
  • Across five years, EBT Margin topped out at 21.78% in Q3 2024 and bottomed at 10185.24% in Q1 2024.
  • Average EBT Margin over 5 years is 1819.13%, with a median of 200.77% recorded in 2022.
  • Year-over-year, EBT Margin tumbled -1019874bps in 2024 and then soared 1001850bps in 2025.
  • Sangamo Therapeutics' EBT Margin stood at 166.66% in 2021, then dropped by -14bps to 189.92% in 2022, then crashed by -1462bps to 2966.06% in 2023, then skyrocketed by 88bps to 366.51% in 2024, then rose by 27bps to 266.88% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 266.88%, 6039.76%, and 109.03% for Q4 2025, Q3 2025, and Q2 2025 respectively.